Overall, the detection of the BRAF V600 mutation plays a predictive role in the management of MM patients, identifying those with a potential sensitivity to combined treatments with BRAF and MEK inhibitors, either in advanced (stage IV or unresectable stage III) or resectable high-stage disease [24,25]. The gene discussed is MAP2K7; the disease is Miyoshi myopathy.